Synonym
CGS 25462; Cgs25462; Cgs-25462
IUPAC/Chemical Name
beta-Alanine, N-(3-(1,1'-biphenyl)-4-yl-N-((diphenoxyphosphinyl)methyl)-L-alanyl)-
InChi Key
JTQWXNZXTRVPHN-LJAQVGFWSA-N
InChi Code
InChI=1S/C31H31N2O6P/c34-30(35)20-21-32-31(36)29(22-24-16-18-26(19-17-24)25-10-4-1-5-11-25)33-23-40(37,38-27-12-6-2-7-13-27)39-28-14-8-3-9-15-28/h1-19,29,33H,20-23H2,(H,32,36)(H,34,35)/t29-/m0/s1
SMILES Code
O=C(O)CCNC([C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)NCP(OC3=CC=CC=C3)(OC4=CC=CC=C4)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
558.57
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Maniara WM, Cipriano A, Powell ML. Quantitative analytical methods for the determination of a new hypertension drug, CGS 25462, and its metabolites (CGS 25659 and CGS 24592) in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1998 Mar 20;706(2):287-94. doi: 10.1016/s0378-4347(97)00566-5. PMID: 9551815.
2: Pu Q, Amiri F, Gannon P, Schiffrin EL. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens. 2005 Feb;23(2):401-9. doi: 10.1097/00004872-200502000-00023. PMID: 15662229.
3: Pu Q, Touyz RM, Schiffrin EL. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. J Hypertens. 2002 May;20(5):899-907. doi: 10.1097/00004872-200205000-00025. PMID: 12011651.
4: Trapani AJ, De Lombaert S, Erion MD, Ghai RD, Peppard JV, Lappe RW, Worcel M. The pharmacology of CGS 25462: a potent, orally bioavailable, long-acting inhibitor of neutral endopeptidase 24.11. J Hypertens Suppl. 1993 Dec;11(5):S220-1. PMID: 8158354.
5: De Lombaert S, Erion MD, Tan J, Blanchard L, el-Chehabi L, Ghai RD, Sakane Y, Berry C, Trapani AJ. N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors. J Med Chem. 1994 Feb 18;37(4):498-511. doi: 10.1021/jm00030a009. PMID: 8120868.
6: Perlini S. The potential advantage of omapatrilat: dual anti-fibrotic and anti-inflammatory effects in one single molecule. J Hypertens. 2005 Feb;23(2):273-5. doi: 10.1097/00004872-200502000-00007. PMID: 15662213.
